A Study of EH002 Gene Therapy for Otoferlin Gene Mutation-mediated Hearing Loss
NCT06722170
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
24
Enrollment
OTHER
Sponsor class
Conditions
DFNB9
Congenital Hearing Loss
Hearing Loss, Sensorineural
Interventions
GENETIC:
EH002 administration
Sponsor
Yilai Shu